Aveo Pharmaceuticals Inc: (NASD: AVEO)
$2.90
0.01 (0.35%)
Volume 1,256,297
May 21 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 2.88 - 3.01 |
| 52wk Low - High | 2.25 - 14.08 |
| Previous Close | 2.89 |
| Avg. Volume | 4,527,403 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 149.81 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.67 |
| PE (Forward) | 0.00 |
| Current Year Est. | -2.25 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -2.25 |
| Current Quarter Estimate | -0.59 |
| Most Accurate Estimate | -0.59 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | -2.51 |
| Expected Earnings Growth | NA |
Company Description
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.59 | -0.47 | -2.25 | -1.96 |
| Number of Estimates | 5 | 5 | 5 | 5 |
| Low Estimate | -0.73 | -0.67 | -2.83 | -2.60 |
| High Estimate | -0.52 | -0.33 | -1.61 | NA |
| Year Ago EPS | -0.68 | -0.69 | -2.60 | -2.25 |
| EPS Growth | 12.65% | 31.30% | 13.62% | 12.64% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| AVEO PHARMACEUT | AVEO | 2.89 | |
|
| AETERNA ZENTARS | AEZS | 2.06 | |
|
| ANIKA THERAPEUT | ANIK | 14.39 | |
|
| GENTIUM SPA-ADR | GENT | 8.84 | |
|
| AASTROM BIOSCI | ASTM | 0.59 | |
|
| ACHILLION PHARM | ACHN | 7.55 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.27 | |
|
| ALEXION PHARMA | ALXN | 100.03 | |
|
| ALKERMES INC | ALKS | 31.04 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Zacks Bull and Bear of the Day Highlights: Private Bancorp, Pan American Silver, AVEO Pharmaceuticals, Astellas Pharma and Cleveland BioLabs
May 06, 2013
Negative Opinion on AVEO/ALPMY Candidate
May 03, 2013
Panel to Review AVEO/ALPMY's Drug
Mar 06, 2013
Data on AVEO/ALPMY's Tivozanib
Feb 13, 2013
Zacks #1 Rank Additions for Tuesday
Oct 23, 2012
Zacks #1 Rank Additions for Wednesday
Oct 17, 2012
Zacks #1 Rank Additions for Wednesday
Oct 10, 2012
XOMA Enrolls for Gevokizumab Trials
Jul 06, 2012
Financials
| EPS TTM | -2.51 |
| Sales | 19 |
| Net Income | -115 |
| Price/Earnings | NA |
| Price/Book | 1.06 |
| Price/Cash Flow | NA |
| Price/Sales | 7.99 |
News
Law Offices of Todd M. Garber Announces Investigation of AVEO Pharmaceuticals, Inc. - Businesswire
May 20, 2013
NVGN, AVEO, QQEW, Removed From Naked Short Lists Today - M2
May 20, 2013
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm - Pr Newswire
May 18, 2013
Aveo Pharmaceuticals, Inc. Sued by Investor - Pr Newswire
May 17, 2013
Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- AVEO - Globenewswire
May 17, 2013
AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting - Businesswire
May 15, 2013
Aveo Screwed Up But Its Kidney Cancer Drug Is Real - TheStreet.com
May 15, 2013
Aveo Screwed Up but Its Kidney Cancer Drug Is Real - TheStreet.com
May 15, 2013
Broker Recommendations
| Current ABR | 3.25 |
| ABR (Last Week) | 3.25 |
| # of recs in ABR | 8 |
| Average Target Price | 4.13 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 38 out of 156 |
